Dr. Krop is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
35 Park Street
Smilow Cancer Hospital at Yale-New Haven
New Haven, CT 06511
Summary
- Ian Krop, MD, PhD is the Chief Clinical Research Officer and Associate Cancer Center Director for Clinical Research at the Yale Cancer Center. He also serves as the Chief Scientific Officer for the Translational Breast Cancer Research Consortium (TBCRC).
Dr. Krop received his undergraduate, medical and PhD degrees from Johns Hopkins University. He subsequently completed his residency in Internal Medicine at Johns Hopkins Hospital, and fellowship in hematology and medical oncology at Dana-Farber.
Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugates trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan
Education & Training
- Johns Hopkins University School of MedicinePhD, 1996
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1999 - 2002
- Johns Hopkins University School of MedicineResidency, 1996 - 1999
- Johns Hopkins University School of MedicineClass of 1996
Certifications & Licensure
- FL State Medical License 2023 - Present
- CT State Medical License 2022 - 2025
- MA State Medical License 2002 - 2023
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 71 citationsSurvival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positi...Aranzazu Fernandez-Martinez, Ian E. Krop, David W. Hillman, Mei Yin C. Polley, Joel S. Parker
Journal of Clinical Oncology. 2020-10-23 - 928 citationsCDK4/6 inhibition triggers anti-tumour immunityShom Goel, Molly J. DeCristo, April C. Watt, Haley BrinJones, Jaclyn Sceneay
Nature. 2017-08-24 - 654 citationsIncidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysisRomualdo Barroso-Sousa, William T. Barry, Ana C. Garrido-Castro, F. Stephen Hodi, Le Min
JAMA Oncology. 2017-09-28
Press Mentions
- Maximizing ADCs in Breast Cancer: Targets, Sequencing, and MoreJune 13th, 2023
- Will HER3 Targeting Change Breast Cancer Care?July 6th, 2023
- Palliative Care for Lung Cancer Via Video? Telehealth “Very Viable Option,” Study ShowsJune 5th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: